NCT06564805

Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Universidad Autonoma de Nuevo Leon · Academic / Other
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Candida Albicans Antigen Injection	subcutaneous administration of Candida albicans antigen

Timeline

• Start date: 2024-08-20
• Primary completion: 2025-07-30
• Completion: 2025-12-31
• First posted: 2024-08-21
• Last updated: 2024-08-21

Locations

1 site across 1 country: Mexico